Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Jack Allen - Robert W. Baird Phil Nadeau - TD Cowen Pete Stavropoulos - Cantor Fitzgerald Lili Nsongo - Leerink Partners Samantha Semenkow - Citi Mehdi Goudarzi - Truist Securities Ry Forseth - Guggenheim Securities Jay Olson - Oppenheimer & Co. Patrick Trucchio - HC Wainwright & Co. Yun Zhong - Wedbush Sciences Yanan Zhu - Wells Fargo Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon, and welcome to Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call.
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago.
- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile -
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.